Novo Nordisk A/S: Financial Statement - Novo Nordisk increased operating profit by 18% in 2011

By: Novo Nordisk A/S via Marketwired News Releases

Posted on February 02, 2012 at 01:44 AM EST

BAGSVAERD, DENMARK -- (Marketwire) -- 02/02/12 --

Sales growth of 9% driven by Victoza®, NovoRapid® and Levemir®

Company Announcement no 7 / 2012: http://hugin.info/2013/R/1581997/494216.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1581997]

Media:

Mike Rulis
Tel: (+45) 4442 3573
Email Contact

In North America
Ken Inchausti
Tel: (+1) 609 786 8316
Email Contact

Investors:
Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact

Further information about Novo Nordisk is available on the company's website
novonordisk.com

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates